Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

Regulation of the human TRAIL gene

(2012) Joshua E. Allen et al.   CANCER BIOLOGY & THERAPY

Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes

(2012) J. E. Allen et al.   MOLECULAR CANCER THERAPEUTICS

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

(2011) Hiromichi Ebi et al.   JOURNAL OF CLINICAL INVESTIGATION

Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis

(2011) Julien van Grevenynghe et al.   JOURNAL OF CLINICAL INVESTIGATION

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

(2011) Theonie Anastassiadis et al.   NATURE BIOTECHNOLOGY

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death

(2010) Kageaki Kuribayashi et al.   CANCER BIOLOGY & THERAPY

Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer

(2010) Jer-Yen Yang et al.   CANCER RESEARCH

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

TRAIL receptor signaling and therapeutics

(2010) Junaid Abdulghani et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

A Better TRAIL Variant for Tumor Cell-Specific Targeting? - Letter

(2010) E. Bremer et al.   MOLECULAR CANCER THERAPEUTICS

Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells

(2009) Soo-Jung Park et al.   CELLULAR SIGNALLING

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

(2009) C. H. Mom et al.   CLINICAL CANCER RESEARCH

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

(2009) Stephen Leong et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy

(2009) Lata G. Menon et al.   STEM CELLS

Synthesis of New Pyrrolo[1,2-a]quinoxaline Derivatives as Potential Inhibitors of Akt Kinase

(2008) Vanessa Desplat et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

(2008) F. Anthony Greco et al.   LUNG CANCER

ERK and MDM2 prey on FOXO3a

(2008) Wensheng Yang et al.   NATURE CELL BIOLOGY

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

(2008) Jer-Yen Yang et al.   NATURE CELL BIOLOGY

FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells

(2008) A N Cornforth et al.   ONCOGENE